Literature DB >> 26852137

MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study.

Roberta Biundo1, L Weis2, S Bostantjopoulou3, E Stefanova4, C Falup-Pecurariu5, M G Kramberger6, G J Geurtsen7, A Antonini2, D Weintraub8, D Aarsland9,10.   

Abstract

The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson's disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen's d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen's effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects.

Entities:  

Keywords:  Dementia with Lewy bodies; MMSE; MoCA; Parkinson disease; Rate of cognitive decline

Mesh:

Year:  2016        PMID: 26852137      PMCID: PMC4820017          DOI: 10.1007/s00702-016-1517-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  38 in total

1.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Sample size planning for the coefficient of variation from the accuracy in parameter estimation approach.

Authors:  Ken Kelley
Journal:  Behav Res Methods       Date:  2007-11

3.  The analysis of 2 × 2 contingency tables--yet again.

Authors:  John T E Richardson
Journal:  Stat Med       Date:  2011-04-15       Impact factor: 2.373

4.  Risk factors for dementia in Parkinson's disease: effect of education.

Authors:  S L Glatt; J P Hubble; K Lyons; A Paolo; A I Tröster; R E Hassanein; W C Koller
Journal:  Neuroepidemiology       Date:  1996 Jan-Feb       Impact factor: 3.282

5.  Reasons for admission to hospital for Parkinson's disease.

Authors:  J A Temlett; P D Thompson
Journal:  Intern Med J       Date:  2006-08       Impact factor: 2.048

6.  The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease.

Authors:  David J Gill; Arielle Freshman; Jennifer A Blender; Bernard Ravina
Journal:  Mov Disord       Date:  2008-05-15       Impact factor: 10.338

7.  Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan.

Authors:  Carol Sheei-Meei Wang; Ming-Chyi Pai; Pai-Lien Chen; Nien-Tsen Hou; Pei-Fang Chien; Ying-Che Huang
Journal:  Int Psychogeriatr       Date:  2013-08-07       Impact factor: 3.878

8.  Combined effect of age and severity on the risk of dementia in Parkinson's disease.

Authors:  Gilberto Levy; Nicole Schupf; Ming-Xin Tang; Lucien J Cote; Elan D Louis; Helen Mejia; Yaakov Stern; Karen Marder
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

9.  A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.

Authors:  Cindy Zadikoff; Susan H Fox; David F Tang-Wai; Teri Thomsen; Rob M A de Bie; Pettarusup Wadia; Janis Miyasaki; Sarah Duff-Canning; Anthony E Lang; Connie Marras
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

10.  Nonlinear decline of mini-mental state examination in Parkinson's disease.

Authors:  Dag Aarsland; Graciela Muniz; Fiona Matthews
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

View more
  30 in total

Review 1.  Differentiation of atypical Parkinson syndromes.

Authors:  Günter U Höglinger; Jan Kassubek; Ilona Csoti; Reinhard Ehret; Heinz Herbst; Ingmar Wellach; Jürgen Winkler; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2017-02-27       Impact factor: 3.575

2.  Effects of Normative Adjustments to the Montreal Cognitive Assessment.

Authors:  Erika A Pugh; Emily C Kemp; Christopher H van Dyck; Adam P Mecca; Emily S Sharp
Journal:  Am J Geriatr Psychiatry       Date:  2018-09-21       Impact factor: 4.105

3.  Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Authors:  Achinoam Faust-Socher; Sarah Duff-Canning; Arthur Grabovsky; Melissa J Armstrong; Brandon Rothberg; Paul J Eslinger; Christopher A Meaney; Ruth B Schneider; David F Tang-Wai; Susan H Fox; Cindy Zadikoff; Nancy Kennedy; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; William Reginold; Connie Marras
Journal:  Dement Geriatr Cogn Disord       Date:  2019-07-17       Impact factor: 2.959

4.  Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort.

Authors:  Milica G Kramberger; Bjørn Auestad; Sara Garcia-Ptacek; Carla Abdelnour; Josep Garre Olmo; Zuzana Walker; Afina W Lemstra; Elisabet Londos; Frederic Blanc; Laura Bonanni; Ian McKeith; Bengt Winblad; Frank Jan de Jong; Flavio Nobili; Elka Stefanova; Maria Petrova; Cristian Falup-Pecurariu; Irena Rektorova; Sevasti Bostantjopoulou; Roberta Biundo; Daniel Weintraub; Dag Aarsland
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.

Authors:  Eleonora Fiorenzato; Luca Weis; Cristian Falup-Pecurariu; Stefania Diaconu; Chiara Siri; Elisa Reali; Gianni Pezzoli; Patrizia Bisiacchi; Angelo Antonini; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2016-06-22       Impact factor: 3.575

6.  Differences in cognitive profiles between Lewy body and Parkinson's disease dementia.

Authors:  Alice Martini; Luca Weis; Roberta Schifano; Francesca Pistonesi; Eleonora Fiorenzato; Angelo Antonini; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2020-01-02       Impact factor: 3.575

7.  Montreal Cognitive Assessment as a screening tool: Influence of performance and symptom validity.

Authors:  Brigid Waldron-Perrine; Nicolette M Gabel; Katharine Seagly; A Zarina Kraal; Percival Pangilinan; Robert J Spencer; Linas Bieliauskas
Journal:  Neurol Clin Pract       Date:  2019-04

8.  Effectiveness of a dance-physiotherapy combined intervention in Parkinson's disease: a randomized controlled pilot trial.

Authors:  Elisa Frisaldi; Piero Bottino; Margherita Fabbri; Marco Trucco; Alessandra De Ceglia; Nadia Esposito; Diletta Barbiani; Eleonora Maria Camerone; Federico Costa; Cristina Destefanis; Edoardo Milano; Giuseppe Massazza; Maurizio Zibetti; Leonardo Lopiano; Fabrizio Benedetti
Journal:  Neurol Sci       Date:  2021-03-20       Impact factor: 3.307

9.  The effect of levodopa on bilateral coordination and gait asymmetry in Parkinson's disease using inertial sensor.

Authors:  Minji Son; Seung Hwan Han; Chul Hyoung Lyoo; Joo Ae Lim; Jeanhong Jeon; Kee-Bum Hong; Hoon Park
Journal:  NPJ Parkinsons Dis       Date:  2021-05-14

10.  β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.

Authors:  Daniel Ferreira; Scott A Przybelski; Timothy G Lesnick; Afina W Lemstra; Elisabet Londos; Frederic Blanc; Zuzana Nedelska; Christopher G Schwarz; Jonathan Graff-Radford; Matthew L Senjem; Julie A Fields; David S Knopman; Rodolfo Savica; Tanis J Ferman; Neill R Graff-Radford; Val J Lowe; Clifford R Jack; Ronald C Petersen; Brit Mollenhauer; Sara Garcia-Ptacek; Carla Abdelnour; Jakub Hort; Laura Bonanni; Ketil Oppedal; Milica G Kramberger; Bradley F Boeve; Dag Aarsland; Eric Westman; Kejal Kantarci
Journal:  Neurology       Date:  2020-09-28       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.